Article Text

PDF
Treatment with a CO-releasing molecule (CORM-3) reduces joint inflammation and erosion in murine collagen-induced arthritis
  1. M L Ferrándiz1,
  2. N Maicas1,
  3. I Garcia-Arnandis1,
  4. M C Terencio1,
  5. R Motterlini2,
  6. I Devesa3,
  7. L A B Joosten3,
  8. W B van den Berg3,
  9. M J Alcaraz1
  1. 1
    Department of Pharmacology, University of Valencia, Valencia, Spain
  2. 2
    Vascular Biology Unit, Department of Surgical Research, Northwick Park Institute for Medical Research, Harrow, Middlesex, UK
  3. 3
    Rheumatology Research & Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
  1. Professor M J Alcaraz, Department of Pharmacology, University of Valencia, Avda. Vicent Andrés Estellés s/n, 46100 Burjassot, Valencia, Spain; maria.j.alcaraz{at}uv.es

Abstract

Objective: CO-releasing molecules (CO-RMs) are a novel class of anti-inflammatory agents. We have examined the possible therapeutic effects of CORM-3 in collagen-induced arthritis (CIA).

Methods: Arthritis was induced in DBA-1/J mice by type II collagen. Animals were treated with CORM-3 (5 and 10 mg/kg/day, intraperitoneally) or the inactive compound iCORM-3 (10 mg/kg/day, intraperitoneally) unable to release CO, from days 22 to 31. Production of anti-type II collagen antibodies, cytokines and cartilage olimeric matrix protein (COMP) was evaluated by enzyme-linked immunosorbent assay, and prostaglandin E2 (PGE2) by radioimmunoassay. Localisation of cyclooxygenase-2 (COX-2), haem oxygenase-1 (HO-1), intercellular adhesion molecule-1 (ICAM-1) and receptor activator of nuclear factor κB ligand (RANKL) was examined by immunohistochemistry.

Results: Therapeutic administration of CORM-3 suppressed clinical and histopathological manifestations of disease. The levels of PGE2, interleukin (IL)1β, IL2, IL6, IL10 and tumour necrosis factor (TNF)α in joint tissues were inhibited by CORM-3. By contrast, CORM-3 augmented IL4. Anti-type II collagen antibodies and COMP levels in serum were reduced by CORM-3. Treatment with CORM-3 decreased cellular infiltration, joint inflammation and destruction, as well as the expression of COX-2, ICAM-1 and RANKL, whereas HO-1 increased. These beneficial effects were due to CO release, as iCORM-3 was ineffective.

Conclusion: This study reveals the antiarthritic properties of CORM-3 in the CIA model and supports the notion that CO-RMs could be developed as a novel strategy for the treatment of inflammatory and arthritic conditions.

Statistics from Altmetric.com

Footnotes

  • Funding: This work was funded by public grants from Spanish Ministerio de Educación y Ciencia-FEDER (SAF2004-03835 and N Maicas fellowship) and Generalitat Valenciana (ACOMP2007-066, GV06/357 and I Garcia-Arnandis fellowship).

  • Competing interests: RM has financial interests in Hemocorm.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.